Global Herpes Zoster Infection Treatment Market Size (2024 - 2029)

The herpes zoster infection treatment market is anticipated to experience growth over the forecast period, driven by factors such as the increasing geriatric population, heightened awareness of varicella vaccinations, and strategic initiatives by market players, including product launches and mergers. The market's expansion is influenced by the high prevalence of herpes zoster, particularly among the elderly, who are more susceptible due to weakened immune systems. Despite the positive outlook, challenges such as the high cost of vaccines may impede market growth. The impact of COVID-19 on the market was significant, affecting supply chains and immunological responses, but stability is expected as the pandemic's effects wane.

Market Size of Global Herpes Zoster Infection Treatment Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Herpes Zoster Infection Treatment Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 4.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Herpes Zoster Infection Treatment Market  Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Herpes Zoster Infection Treatment Market Analysis

During the time frame of the forecast, the herpes zoster infection treatment market is expected to register a CAGR of 4.1%.

COVID-19 had a significant impact on the growth of the market. Herpes zoster infection is caused by the reactivation of the varicella-zoster virus, which can occur in patients who have immunosuppressive diseases or whose cell-mediated immunity declines with age. Coronavirus infection has also been linked to T-cell immunological dysfunction and can result in Herpes zoster reactivation.For instance, as per the study published by PubMed in July 2022 on COVID-19 individuals, varicella-zoster virus reactivation could occur as a result of T-cell malfunction, such as lymphopenia and lymphocyte depletion. Patients with COVID-19 were more likely to reactivate herpes zoster due to the tendency of COVID-19 to establish an immunosuppressive state, related to the functional impairment and the concurrent quantitative drop in T lymphocytes, especially cd4+ T cells, cd8+ T cells, and natural killer cells. Additionally, the COVID-19 pandemic also disrupted the supply chain of antiviral drugs, which had a negative impact on the studied market. For instance, according to an article published by PubMed in May 2022, antiviral drug purchases significantly decreased in developed countries during the early pandemic. Therefore, the COVID-19 pandemic had a pronounced impact on the growth of the market. However, as the pandemic has currently subsided, the studied market is expected to have stable growth during the forecast period of the study.

The key market drivers for the growth of the herpes zoster infection treatment market include the rising geriatric population coupled with the rising incidence of herpes zoster, growing awareness regarding the use of the varicella vaccine, and an increase in immunization programs across the world. Herpes zoster (HZ) has a cumulative incidence rate of 2.9-19.5 cases per 1,000 population and an incidence rate of 5.23-10.9 cases per 1,000 person-years, according to a study published in PubMed in March 2021.Females had higher cumulative incidence and incidence rates than males. Because of weak immune systems, elderly people are more susceptible to herpes zoster. The geriatric population is expected to have a significant impact on the market studied as people over 65 are more susceptible to chronic diseases. For instance, according to the study updated by the NCBI in September 2022, herpes zoster occurs at a rate of 1.2 to 3.4 per 1000 people per year in younger, healthy people, but at a rate of 3.9 to 11.8 per 1000 people per year in patients over 65. Hence, herpes zoster is more prevalent in the aging population.

Moreover, the growing geriatric population is expected to positively impact market growth. For instance, according to the World Population Prospect 2022, the global population of people aged 65 and older is estimated at 77 million in 2022 and is expected to reach 1.6 billion by 2050. As the geriatric population is more susceptible to herpes zoster, the increasing number of cases is expected to boost market growth over the forecast period.

Additionally, the increasing coverage of the herpes zoster vaccine, or shingles vaccine, is also expected to boost market growth. For example, according to data updated by the United Kingdom Government in November 2022, 31.2% of patients aged 70 in the United Kingdom received the shingles vaccine during 2021-2022, while 74.9% of patients aged 76 received the vaccine during the same time period.

Additionally, the market is also driven by increasing awareness about the use of varicella vaccinations and market players adopting various strategies such as product launches, mergers and acquisitions, and fundraising for research and development activity. For instance, in February 2021, Dr. Florian Full of the Institute of Clinical and Molecular Virology at Universitätsklinkum Erlangen at Friedrich-Alexander-Universität (FAU) received EUR 2.34 million in funding from the Federal Ministry of Education and Research (BMBF) for the development of a new herpes virus medication. Such instances may positively impact market growth over the forecast period.

Thus, owing to the aforementioned factors such as the high prevalence of herpes zoster, the growing geriatric population, increasing awareness about the use of varicella vaccinations, and market players adopting various strategies such as product launches, mergers and acquisitions, and fundraising for research and development activity, the market is expected to project growth over the forecast period. However, the high cost of the vaccine is likely to hinder market growth over the coming years.

Herpes Zoster Infection Treatment Industry Segmentation

As per the scope of the report, herpes zoster (shingles) is a viral infection caused by the varicella-zoster virus (chickenpox) reactivating and resulting in a painful dermatomal rash. The rash may appear on the trunk, buttocks, arms, legs, or face. Treatment in the form of vaccines and drug therapy is available for herpes zoster infection. Type (Drug Therapy (Antivirals, Analgesics, Nonsteroidal Anti-inflammatory Drugs, and Others) and Vaccination (Monovalent Vaccine and Combination Vaccine), End User (Hospitals and Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) are the segments of the Herpes Zoster Infection Treatment Market. The report offers the value (in USD million) for the above segments.

By Type
Drug Therapy
Antivirals
Analgesic
Nonsteroidal Anti-inflammatory Drugs
Other Types
Vaccination
Monovalent Vaccine
Combination Vaccine
By End User
Hospitals and Clinics
Diagnostic Centers
Other End-Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
Need A Different Region Or Segment?
Customize Now

Global Herpes Zoster Infection Treatment Market Size Summary

The herpes zoster infection treatment market is poised for steady growth over the forecast period, driven by several key factors. The increasing prevalence of herpes zoster, particularly among the aging population, is a significant contributor to market expansion. As individuals over 65 are more susceptible to this infection due to weakened immune systems, the rising geriatric demographic is expected to bolster market demand. Additionally, heightened awareness and the implementation of immunization programs, such as the varicella vaccine, are further propelling market growth. The market is also witnessing strategic activities by key players, including product launches and research funding, which are aimed at enhancing treatment options and expanding market reach.

The antiviral drug segment holds a substantial share of the market, supported by the availability of effective treatments that reduce viral shedding and alleviate symptoms. The North American region is anticipated to maintain a significant market presence due to the high incidence of herpes zoster and the accessibility of medications. Major companies are actively involved in developing and marketing vaccines, with ongoing clinical trials and regulatory approvals facilitating market advancement. Despite the high cost of vaccines posing a potential challenge, the overall market is expected to benefit from the increasing burden of herpes zoster infections, coupled with rising awareness and new product introductions.

Explore More

Global Herpes Zoster Infection Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Geriatric Population Coupled with Rising incidence of Herpes Zoster

      2. 1.2.2 Growing Awareness Regarding the Use of Varicella Vaccine and Increase in Immunization Programs Across the World

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of the Vaccine

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Type

      1. 2.1.1 Drug Therapy

        1. 2.1.1.1 Antivirals

        2. 2.1.1.2 Analgesic

        3. 2.1.1.3 Nonsteroidal Anti-inflammatory Drugs

        4. 2.1.1.4 Other Types

      2. 2.1.2 Vaccination

        1. 2.1.2.1 Monovalent Vaccine

        2. 2.1.2.2 Combination Vaccine

    2. 2.2 By End User

      1. 2.2.1 Hospitals and Clinics

      2. 2.2.2 Diagnostic Centers

      3. 2.2.3 Other End-Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Rest of the World

Global Herpes Zoster Infection Treatment Market Size FAQs

The Global Herpes Zoster Infection Treatment Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)

GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Apotex Inc. and Viatris Inc. are the major companies operating in the Global Herpes Zoster Infection Treatment Market.

Herpes Zoster Infection Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)